A Study of SYNC-T Therapy SV-102 in Participants With Metastatic Castration-Resistant Prostate Cancer
NCT06533644
This study is recruiting at 14 US sites in 11 states, according to its ClinicalTrials.gov record last updated .
Summary
The primary purpose of this study is to evaluate the safety, tolerability, and efficacy of SYNC-T Therapy SV-102 and to identify the maximum tolerated dose (MTD) and/or selected dose for phase 2b study.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Metastatic Castration-resistant Prostate Cancer
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 2
- Ages
- 18 years and older
- Sex
- Male
- Healthy volunteers
- Not accepted
- Sponsor
- Syncromune, Inc.
- Last updated on ClinicalTrials.gov
- June 23, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Arizona · 1
- University of Arizona Cancer Center · Tucson, AZ
California · 1
- University of California-Davis · Sacramento, CA
Florida · 2
- University of Miami · Miami, FL
- Moffitt Cancer Center · Tampa, FL
Illinois · 1
- Duly Health · Lisle, IL
Kansas · 1
- Wichita Urology · Wichita, KS
Michigan · 1
- Michigan Institute of Urology · Troy, MI
Missouri · 1
- Mercy Hospital · St Louis, MO
Nebraska · 1
- University of Nebraska Medical Center · Omaha, NE
New York · 3
- Northwell Health · Lake Success, NY
- NYU Langone · New York, NY
- Weill Cornell · New York, NY
Ohio · 1
- Ohio State University · Columbus, OH
Pennsylvania · 1
- University of Pittsburgh Medical Center · Pittsburgh, PA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.